Virtual Touch (TM) Quantification to Diagnose and Monitor Liver Fibrosis in Hepatitis B and Hepatitis C: A NICE Medical Technology Guidance by Summers, JA et al.
Virtual Touch™ Quantification to Diagnose and Monitor Liver Fibrosis in
Hepatitis B and Hepatitis C: A NICE Medical Technology Guidance.
Summers, JA; Radhakrishnan, M; Morris, E; Chalkidou, A; Rua, T; Patel, A; McMillan, V;
Douiri, A; Wang, Y; Ayis, S; Higgins, J; Keevil, S; Lewis, C; Peacock, J
 
 
 
 
 
(c) The Author(s) 2016. This article is published with open access at Springerlink.com
This article is distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits any noncommercial use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/15904
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
REVIEW ARTICLE
Virtual TouchTM Quantification to Diagnose and Monitor Liver
Fibrosis in Hepatitis B and Hepatitis C: A NICE Medical
Technology Guidance
Jennifer A. Summers1,2 • Muralikrishnan Radhakrishnan1,3 • Elizabeth Morris1,5 •
Anastasia Chalkidou1,5 • Tiago Rua5 • Anita Patel6 • Viktoria McMillan1,5 •
Abdel Douiri2 • Yanzhong Wang2 • Salma Ayis2 • Joanne Higgins7 •
Stephen Keevil1,5,8 • Cornelius Lewis1,9 • Janet Peacock1,2,4
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Virtual TouchTM Quantification (VTq) is a
software application used with Siemens Acuson ultrasound
scanners to assess the stiffness of liver tissue. The National
Institute for Health and Care Excellence (NICE) Medical
Technologies Advisory Committee (MTAC) selected VTq
for evaluation and invited the company to submit clinical
and economic evidence. King’s Technology Evaluation
Centre, an External Assessment Centre (EAC) commis-
sioned by NICE, independently assessed the evidence
submitted. The EAC conducted its own systematic review,
meta-analysis and economic analysis to supplement the
company’s submitted evidence. The meta-analyses com-
paring VTq and transient elastography (TE) with liver
biopsy (LB) provided pooled estimates of liver stiffness
and stage of fibrosis for the study populations (hepatitis B,
hepatitis C or combined populations). When comparing
significant fibrosis (Metavir score F C 2) for both hepatitis
B and C, VTq had slightly higher values for both sensitivity
and specificity (77 and 81 %) than TE (76 and 71 %). The
overall prevalence of cirrhosis (F4, combined populations)
was similar with VTq and TE (23 vs. 23 %), and significant
fibrosis (F C 2) was lower for VTq than for TE (55 vs.
62 %). The EAC revised the company’s de novo cost
model, which resulted in a cost saving of £53 (against TE)
and £434 (against LB). Following public consultation,
taking into account submitted comments, NICE Medical
Technology Guidance MTG27 was published in September
2015. This recommended the adoption of the VTq software
to diagnose and monitor liver fibrosis in patients with
hepatitis B or hepatitis C.
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Key Points for Decision Makers
Virtual TouchTM Quantification (VTq) is a software
application used with Siemens Acuson ultrasound
scanners to assess the stiffness of liver tissue and the
stage of liver fibrosis.
The National Institute for Health and Care
Excellence Medical Technology Evaluation
Programme assessed the VTq software for use in
people with hepatitis B or C and the External
Assessment Centre estimated cost savings per patient
for the VTq software in hepatitis patients was £53
when compared to transient elastography and £434
when compared to liver biopsy.
In September 2015, the VTq software was
recommended for adoption within the National
Health Service (NHS) for patients with hepatitis B or
C for diagnosis and monitoring of liver fibrosis.
1 Introduction
The role of the National Institute for Health and Care
Excellence (NICE) is to provide guidance and advice to
improve health and social care in England. Evaluating new
or innovative medical technologies for adoption in the
National Health Service (NHS) in England is part of this
role. These evaluations are undertaken by the NICE
Medical Technologies Evaluation Programme (MTEP).
In order for technologies to be eligible for evaluation they
must be new or innovative, have a current CE mark or
equivalent regulatory approval (or be expecting one within
12 months) and be suitable for eventual NICE guidance
within the definitions of a medical or diagnostic technology.
The process and methods for topic selection and guidance
development are described further in the MTEP process and
method guides [1]. Guidance is produced by the Medical
Technologies Advisory Committee (MTAC) after clinical
and cost evidence submitted by the manufacturer is inde-
pendently assessed by an External Assessment Centre
(EAC), and following consideration of comments received
during public consultation on the draft recommendations.
Throughout the evaluation process, input from patient
organisations and independent expert advisers is considered.
Virtual TouchTM Quantification (VTq) is a software
application used with either the Acuson S2000TM or the
Acuson S3000TM ultrasound scanner (Siemens Healthcare,
Erlangen, Germany) to assess the stiffness of liver tissue.
In September 2015, NICE issued final guidance (MTG27)
on this technology specifically in relation to liver fibrosis in
patients with chronic hepatitis B or hepatitis C [2]. This
article presents a summary of the EAC report and its
contribution to the NICE guidance on the use of VTq as
part of a series of NICE Medical Technology Guidance
summaries published in Applied Health Economics and
Health Policy.
2 Decision Problem
2.1 Disease Overview
Viral hepatitis in humans is characterised by inflammation
and damage to the liver such as liver fibrosis, cirrhosis and
hepatocellular carcinoma. Worldwide, viral hepatitis is
considered to be a major public health issue as it is the
cause of significant morbidity and mortality. There are
several types of viral hepatitis: hepatitis A, hepatitis B,
hepatitis C, hepatitis D and hepatitis E. Symptoms of
hepatitis vary; they may include (but are not limited to)
abdominal pain, fever, joint pain, loss of appetite, yel-
lowing of skin and eyes (jaundice), and nausea/vomiting.
Hepatitis B and C are of particular interest for this current
MTEP technology evaluation. Hepatitis B (International
Statistical Classification of Diseases and Related Health
Problems, 10th edition [ICD-10] classification: B17.0,
B16.0, B16.1, B16.9) causes acute and chronic hepatitis and
is largely transmitted through exposure to infected body
fluids such as blood through sexual activity, unsanitary
conditions or breastfeeding. There is a vaccine available that
provides lifetime protection. Worldwide, it is estimated that
chronic infection with hepatitis B affects 400 million people
[3], whilst the British Liver Trust estimates that 1 in 350
people in the UK have chronic hepatitis B [4].
Hepatitis C (ICD-10: B17.1, B18.2) is usually contracted
through exposure to infected blood and through the placenta
during pregnancy. It can remain asymptomatic for several
years, and when symptoms do occur, they are similar to the
symptoms of influenza. Infection with hepatitis C can lead to
chronic hepatitis, resulting in fibrosis (stiffening of the liver)
and cirrhosis of the liver. The World Health Organization
estimate that 130–150 million people have hepatitis C
globally [5] and there is currently no vaccine available. It is
estimated that 215,000 people in the UK have hepatitis C [6]
and that 50 % of those people are undiagnosed [7].
2.2 Risk Assessment and Current Treatment
Options
The NICE guideline on chronic hepatitis B diagnosis and
management recommends that people with hepatitis B are
assessed in primary care and refers to special consideration for
patients who are pregnant or have decompensated liver
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disease and for paediatric patients [8]. In secondary specialist
care, it is recommended that all hepatitisBpatients be assessed
for liver disease using non-invasive tests such as transient
elastography (TE) and/or genotype testing, and, where
deemed necessary/appropriate, they are offered a liver biopsy
(LB) to determine the level of fibrosis and/or antiviral treat-
ment. Recommendations for regular surveillance and moni-
toring of liver disease are outlined in the guidance, along with
specific reference to particular patient subgroupmanagement.
NICE guidelines for hepatitis C are currently being
developed and will be published in September 2016
(https://www.nice.org.uk/guidance/indevelopment/gid-cg
wave0666). Draft guidance in the interim period recom-
mends three different treatment options for patients with
chronic hepatitis C depending on genotype, liver disease
stage and fibrosis stage: daclatasvir, ledipasvir–sofosbuvir
and ombitasvir–partaprevir–ritonavir with or without
dasabuvir [7].
2.3 Virtual TouchTM Quantification (VTq)
VTq is a software application (implementation of acoustic
radiation force impulse [ARFI] technology) used with
either the Acuson S2000TM or the Acuson S3000TM
ultrasound scanners (Siemens Healthcare) to assess the
stiffness (elasticity) of liver tissue. More specifically, ARFI
works by measuring shear wave speed in the liver using an
ultrasound machine, and is usually performed by a sono-
grapher, radiologist or hepatologist. VTq assessment
requires multiple measurements, adding 5–10 min to a
routine abdominal ultrasound examination, and the com-
pany describes it as a non-invasive and pain-free applica-
tion. VTq software reports a statistical summary of both the
median and mean shear wave velocities, and reliability can
be confirmed by calculating a ‘‘ratio of the inter-quartile
range to median, which should be less than 0.30’’ [9].
This assessment report focuses specifically on the use of
VTq in patients with chronic hepatitis B or hepatitis C. The
company provided three CE declarations of conformity; the
Acuson S3000TM declaration of conformity was dated
November 2012. Both ultrasound devices were classified as
Class IIa medical devices.
2.4 NICE Scope
The final scope for the evaluation of VTq to diagnose and
monitor liver fibrosis was developed by NICE in consultation
with stakeholders and published in May 2014. The scope
defined the patient population as ‘‘adults or children with
chronic hepatitis B or C in whom assessment of liver fibrosis
is indicated’’ [10]. The comparators were TE (also referred to
as Fibroscan) (http://www.myliverexam.com/en/lexamen-
fibroscan.html) and the index test of LB. The intervention
was the VTq software application to be ‘‘used with the Sie-
mens Virtual Touch Tissue Imaging systems (the Acuson
S2000 or S3000 ultrasound platforms)’’ [10]. The outcome
measures specified were correlation in assessment of stage of
liver disease, sensitivity and specificity (using area under the
receiver operating characteristic [AUROC], a summary
statistic) in assessment of liver fibrosis, correlation in
assessment of stage of fibrosis using Metavir score (a scoring
system for assessing liver inflammation and fibrosis of the
liver), use of antiviral drugs, quality-of-lifemeasures, hospital
bed usage and length of stay, the requirement for LB, and
device-related adverse events. The Metavir scoring system
provides a validated classification system for development of
fibrosis: F0 = no fibrosis; F1 = portal fibrosis without septa; F2
= portal fibrosis with rare septa; F3 = numerous septa without
cirrhosis; and F4 = cirrhosis.
The scope requested that both comparators (TE and LB)
be included in the cost analysis, depending on ‘‘whether
either or both of these represent standard care in the relevant
patient population’’ [10] and that both primary and sec-
ondary care settings be considered. The model for the cost
analysis was also to consider scenarios where a compatible
Siemens ultrasound machine is and is not available. The
scope did not specify any subgroups or special considera-
tions to be considered which related to equality issues.
3 EAC Review
The company’s submission consisted of clinical and eco-
nomic evidence. The clinical section provided an overview
and systematic review of clinical evidence related to VTq
and the comparators of TE and LB. The company found no
economic evidence relating to VTq, and instead submitted
a de novo cost model. King’s Technology Evaluation
Centre (KiTEC), an EAC based in the King’s Health
Partners Academic Health Science Centre (KHP), was
commissioned by NICE to critique the manufacturer’s
submission and provide further evidence if available.
3.1 Clinical Effectiveness Evidence
The company submitted clinical evidence and a search
strategy relating to the use of VTq with either the Acuson
S2000TM or Acuson S3000TM ultrasound scanners to assess
the stiffness of liver tissue.
Clinical evidence was provided on the intended inter-
vention and both comparators specified in the scope. The
company provided clinical evidence based on 23 studies (a
combination of conference abstracts and full publications)
[11–31]. On further evaluation, the company refined this
evidence to 11 studies for full review, as the other 12
studies ‘‘did not contain sufficient information to complete
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the inclusion assessment’’ [9]. Of the 11 publications that
the company did include for further evaluation, ten were
case-control observational studies [20, 23–27, 29, 32–34]
and one was a meta-analysis [22].
The company stated that they had not been made aware
of any ongoing studies. However, the EAC performed a
search of the clinical trials database (ClinicalTrials.gov)
using the terms ‘ARFI’, ‘VTq’, ‘Virtual Touch tissue
quantification’ and ‘Acoustic Radiation Force Impulse’ and
identified three clinical trials that it considered potentially
relevant [35–37]. The EAC noted that one of these clinical
trials is being conducted in a paediatric population, with an
estimated trial completion date of November 2015 [37].
However, additional data for this age group are only likely
to become available within the next 1–2 years.
3.1.1 Critique of Clinical Effectiveness Evidence
The EAC considered that the company included some of
the relevant evidence on VTq and both comparators and
that the company’s interpretation of the available clinical
evidence was reasonable and provided a fair assessment of
the studies submitted. Of the 11 studies provided by the
company, all fitted the required scope in terms of com-
parators and outcome measures. The majority of these
publications (mainly conference abstracts) provided lim-
ited study details, such as baseline characteristics of
patients (e.g. ethnicity) and study design.
The EAC had several concerns relating to the effec-
tiveness of the company’s study selection: for example,
although the search terms and time limits used by the
company were appropriate for the technology, a large
proportion of the published studies included overlapping
cohorts. Identifying which studies used independent groups
of patients is challenging and this was noted in the com-
pany’s submission and during the clinical evidence sub-
mission discussion teleconference held on 30 June 2014.
Of these 11 company-included studies, eight were sub-
sequently excluded by the EAC as their patient cohorts
overlapped with those of the three studies subsequently
accepted by the EAC [32–34] (Table 1).
The company reported no adverse events in the sub-
mission, and the EAC also did not identify any adverse
events reported in the literature. Expert advisers were asked
if they had any knowledge of adverse events that had
occurred previously or could potentially occur in the future.
No expert adviser responded with any known adverse
events related to this technology.
3.1.2 Additional EAC Clinical Effectiveness Evidence
The EAC noted that there were minor discrepancies in the
description of the company’s systematic review
methodology, such as incomplete search strategy terms.
Clarification was sought from the company, who responded
with the correct search terminology. The EAC replicated
the company’s search strategy but concluded that it lacked
some important search terms. Therefore, the EAC con-
ducted a revised systematic review with additional search
terms related to outcomes as defined in the scope and to
ensure all available evidence had been considered (see
Appendices 1, 2).
A total of 49 studies were selected for full paper review,
of which 39 were rejected. Of the ten studies that the
EAC’s systematic review identified as relevant in terms of
the scope, three were also identified in the company’s own
systematic review: Friedrich-Rust et al. [32, 33] and Sporea
et al. [34]. The findings of the remaining seven EAC-ac-
cepted papers and an overview of each study are presented
in Table 2. It is noted here that two of the studies [38, 39]
were previously identified by the company but were not
included in their final selection. Appendix 3 shows a
PRISMA flow diagram including both the company’s and
the EAC’s search strategies.
3.1.3 EAC Meta-Analyses
All EAC-accepted studies were reviewed and, where
appropriate, population outcome data were extracted in
order to conduct meta-analyses. Where actual frequencies
were not reported in full in the papers they were calculated
using available study summary data (sensitivity, speci-
ficity, totals). Random effects meta-analyses were used to
calculate all pooled proportions for correlation, sensitivity,
specificity and prevalence. Prior to analysis proportions
were transformed using the logit function (log[p/(1 - p)])
as in most cases they were either close to 0 or close to
100 % and so skewed. For positive skewness (log[p/(1 -
p)]) was used, for negative skewness (log[(1 - p)/p]) was
used. For sets of proportions that had a wide range, no
transformation was used prior to pooling. Numerator val-
ues of 0 (in specificity) were replaced with 0.5 to permit
pooling. Results of meta-analyses were back-transformed
to the natural scale as appropriate. All analyses were
conducted using STATA v11.0 (STATA Corp. LP,
College Station, TX, USA). The ‘metan’ procedure was
used for the random effects meta-analyses.
Pooled values were calculated for each study population
(i.e. hepatitis B, hepatitis C and combined) and then for the
liver fibrosis comparator (i.e. VTq and TE) to LB for all
liver fibrosis stages (where available). In cases where only
a single study was available, the appropriate proportion and
95 % confidence interval (CI) were calculated. In all, nine
outcome estimates were calculated with 95 % CIs for
prevalence, sensitivity and specificity (Table 3). Six further
estimates are given using single study data.
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Correlation values were pooled for nine studies
(Table 3). Most papers reported Spearman’s rank correla-
tion (rho), but Yamada et al. [39] used Pearson’s correla-
tion coefficient (r). In order to provide a pooled correlation
for the Spearman’s rho, the large sample approximation for
the variance of rho was calculated as 1/(N - 1), where N is
the total number of subjects from whom the correlation was
calculated. Since it is not possible to pool values of rho and
r, Yamada et al.’s value was considered to be a Spearman’s
rho coefficient for meta-analysis. Sensitivity analysis
without Yamada et al.’s study made virtually no difference
to pooled estimates and so the pooled values including
Yamada et al. [39] are reported. The 95 % CIs are only
provided where the number of values to be combined is
sufficient to give a stable estimate.
The meta-analyses provided estimates with 95 % CIs for
prevalence, sensitivity and specificity (Table 4). In all, nine
pooled outcome estimates were calculated for significant
fibrosis (F C 2) and both hepatitis B and C were lower with
VTq (55 %) than TE (62 %); however, the techniques had
similar scores for cirrhosis (F4): VTq, 23 % and TE, 23 %.
The results for specificity in all subgroups ranged from 71
to 87 %, while for sensitivity the values ranged more
widely, from 70 to 93 %. The range of values for both
sensitivity and specificity were similar for both the hep-
atitis B and hepatitis C study populations. When comparing
significant fibrosis (F C 2) for both hepatitis B and C, VTq
had slightly higher values for both sensitivity and speci-
ficity (77 and 81 %) than TE (76 and 71 %). Sensitivity
values were higher than specificity for cirrhosis (F4) in the
combined study population for VTq (85 and 80 %), whilst
the opposite was found for TE (79 and 84 %). However,
the values were similar for both VTq and TE.
The meta-analyses of correlation coefficients for VTq
and TE gave pooled estimates ranging from 0.63 to 0.69
(Table 5). The combined study population correlation
coefficients for VTq and TE were similar (0.68 and 0.69,
respectively).
As expected, prevalence rates generally decreased with
increasing liver fibrosis stage. Overall prevalence for both
VTq and TE (combined study populations) had similar
rates for cirrhosis (F4) (0.23 vs. 0.23) and a lower preva-
lence for significant fibrosis (F C 2) for VTq when com-
pared with TE (0.55 vs. 0.62). Pooled estimates (combined
study populations) for correlation were similar for VTq and
TE, whilst the pooled estimates for sensitivity for
Table 1 Summary of key points from the company-included studies accepted by the External Assessment Centre
Study Patient population and
country
Intervention
and/or
comparator
Study design Main findings
Friedrich-
Rust
et al.
[33]
Hepatitis C (n = 253)
Germany, Netherlands,
Romania
VTq vs. TE,
LB
Crossover; international multicentre
study
Abstract
Compared AUROC values of both VTq
vs. TE (intention to diagnose) and VTq
vs. TE (per protocol) and found that the
only significant comparison was VTq
vs. TE (intention to diagnose) F C 2
(p = 0.03)
Found a significant correlation between
VTq and TE with histological fibrosis
stage
Friedrich-
Rust
et al.
[32]
Hepatitis B (n = 114)
Germany, Netherlands
VTq vs. TE,
LB
Prospective, cohort, multicentre study.
Receiver operating curves used for
comparisons at different levels of
severity based on histology (liver
fibrosis)
Full paper
Found no significant overall correlation; a
highly significant correlation was found
between VTq and liver fibrosis stage
(Spearman r = 0.65, p\ 0.001)
Documented sensitivity and specificity
values using AUROC for fibrosis stage
with confidence intervals and when
comparing VTq to TE, they found no
significant difference for either
intention to diagnose or per protocol
between TE and VTq
Sporea
et al.
[34]
Hepatitis C (n = 914), 911
valid cases
Japan, Romania, Germany,
Italy, Austria
VTq vs. TE,
LB
Retrospective cohort, multicentre study.
Correlation used to assess reliability,
using Spearman test
A subgroup of 400 patients with chronic
hepatitis C assessed by ARFI and TE
Full paper
Concluded that TE was significantly
better than VTq for predicting presence
of liver cirrhosis (p = 0.01) and fibrosis
(p = 0.01), but found no significant
difference for predicting severe fibrosis
ARFI acoustic radiation force impulse, AUROC area under receiver operating characteristic, LB liver biopsy, TE transient elastography, VTq
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Table 2 Summary of key points from additional studies included in the External Assessment Centre systematic review (n = 7)
Study Patient population and country Intervention and/or
comparator
Study design Main findings
Chen et al.
[40]
Patients with hepatitis C
(n = 127)
Taiwan/China
VTq, liver biopsy Prospective, observational,
operator-blind study. Liver
biopsy within 1 h of ARFI
measurements (Acuson
S2000TM). No follow-up
Found a statistically significant
correlation (r = 0.70,
p\ 0.001) (with all AUROC
values above 0.83) between
ARFI and liver biopsy.
However, the degree of
concurrent hepatic necro-
inflammatory activity
significantly affected the
measurements of liver fibrosis
using ARFI
Kuroda
et al. [41]
n = 30 patients with hepatitis C,
n = 30 patients with liver
cirrhosis, and n = 10 healthy
subjects (controls)
Japan
VTq, biochemical tests,
liver biopsy
Prospective, diagnostic accuracy
study. Biochemical tests
performed on the same day as
ARFI measurements. Timing
of liver biopsy unclear
Diagnosis of liver cirrhosis using
ARFI (AUROC: 0.930 [no
CI]). The most appropriate cut-
off value for shear wave
velocity values was 1.59
(sensitivity 95 %, specificity
83 %)
Liu et al.
[38]
Patients with hepatitis B
(n = 95) and 16 healthy
volunteers
China
VTq, liver biopsy, TE Prospective, diagnostic
accuracy, ARFI measurement
with Siemens Acuson
S2000TM within 1 day of liver
biopsy. No follow-up
Both ARFI and TE had similar
AUROC values for both the
intermediate (F2) and
advanced (F4) fibrosis stages
Nishikawa
et al. [42]
Patients with hepatitis C
(n = 108)
Japan
VTq, liver biopsy Prospective diagnostic accuracy,
ARFI measurement with
Siemens Acuson S2000TM
within 1 week of liver biopsy.
Patients underwent a liver
biopsy before starting
treatment with interferon. No
follow-up
Found that ARFI correlated
significantly with liver fibrosis
stage in all patients.
Additionally, ARFI correlated
significantly with BMI, GTP
and hyaluronic acid blood
levels in fibrosis stages F0–1,
F2 and F3–4, respectively.
ARFI measurements did not
correlate with inflammation
Rizzo et al.
[43]
Patients with hepatitis C
(n = 139)
Italy
VTq, liver biopsy, TE Prospective, diagnostic
accuracy, percutaneous liver
biopsy and ARFI/TE
measurements (Acuson
S2000TM) within 6 months. No
follow-up
Found that ARFI imaging was
reproducible and accurate for
staging of both intermediate
([F2) and advanced (F3–4)
liver fibrosis. The AUROC
results for these stages were
comparable with the
performance of TE
Yamada
et al. [39]
Patients with hepatitis C
(n = 124)
Japan
VTq, peg-IFN plus
ribavirin combination
therapy. Liver fibrosis
assessed histologically
by liver biopsy,
response to treatment
measured with serum
hepatitis C RNA
levels and ARFI
Diagnostic accuracy and
prediction of response to
treatment, prospective status
not clear, ARFI measurement
(Acuson S2000TM) was
performed within 1 week
preceding liver biopsy.
Follow-up was at weeks 4, 12,
24, 36, and 48, end of
treatment and week 24 after
the treatment for genotype 1.
For genotype 2, follow-up was
at weeks 4, 12 and 24, and
week 24 after the treatment
The shear velocity value
increased with the progression
of the histological fibrosis
stage, as assessed using the
Metavir scoring system, and a
significant correlation was
found between the two
variables (Pearson product–
moment correlation coefficient
= 0.764 (p\ 0.001). The
AUROCs were F C 2 (0.890)
and F C 3 (0.943). The shear
velocity value measured by
ARFI could not predict the
treatment response for patients
with hepatitis C genotype 2 but
showed some benefit for
patients with genotype 1
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significant fibrosis (F C 2) and cirrhosis (F4) were higher
for VTq than for TE. Specificity values for significant
fibrosis (F C 2) were notably higher for VTq than TE (81
vs. 71 %), but were closer for cirrhosis (F4) (80 vs. 84 %).
The EAC notes that caution must be observed when
interpreting the results from the meta-analyses as no
adjustment was possible for confounding variables such as
patient characteristics, other than hepatitis type, research
design and research settings (such as country).
3.2 Economic Evidence
The company submitted details of the search strategy
designed to retrieve relevant health economics studies from
published and unpublished literature from 2009 to 2014.
They concluded that no economic evidence was available
for VTq and hence submitted a de novo cost model. The
company provided a decision-tree model using 2013 prices
from the UK NHS and personal social services perspective
to estimate the cost for VTq and the comparators. The time
horizon for the model was 1 year. The company’s mod-
elling approach was based on a 2009 economic report from
the Centre for Evidence-based Purchasing [45]. However,
this report does not include the distribution of different
stages of liver fibrosis (i.e. F1–F4 using the Metavir score).
Therefore, this model would not fully capture the decision
problem stated in the scope issued by NICE. In order to
mitigate this issue, the company submitted a revised model
using a sequential distribution of liver fibrosis stage (ac-
cording to Metavir score). This is achieved by sequentially
separating the overall prevalence of liver fibrosis in three
stage groups: (1) F C 2; (2) F C 3; and (3) F4. The mod-
elling was developed using two parameters: (1) estimated
prevalence of liver fibrosis for different stages; and (2) the
sensitivity/specificity of each strategy (i.e. VTq and the
comparators [TE and LB]) at different liver fibrosis stages.
Based on these parameters, all patients were categorised as
(1) true positive; (2) true negative; (3) false positive; or (4)
false negative.
Prevalence estimates were based on expert opinion
provided by four clinicians who had familiarity with VTq
and Fibroscan. The diagnostic accuracy for TE was based
on a published meta-analysis [46]. LB was assumed to have
perfect (i.e. 100 %) sensitivity and specificity, as it is the
reference test for diagnosing liver fibrosis. The sensitivity
and specificity of VTq for different stages of liver fibrosis
were estimated as an average from different published
studies, i.e. not from a meta-analysis
[22, 24, 25, 27, 29, 30, 39, 44, 47–51].
The company had undertaken and presented a bottom-up
approach for costing the technology (VTq; £15.02 per
scan) and one of the comparators (TE; £25.33 per scan), as
there were no specific tariffs that accurately reflect differ-
ences in resource use. The biopsy unit cost (£615 per LB)
was estimated from the 2013 to 2014 payment by results
(PbR) tariff. The company performed several deterministic
one-way and multi-way sensitivity analyses, varying the
prevalence of liver fibrosis, VTq’s diagnostic accuracy,
specific costs (e.g. unit cost per VTq examination) and
biopsy utilisation after initial diagnostic ultrasound.
The company reported a cost saving of £10.31 per
patient by using VTq compared with TE. In comparison
with LB, the company reported that VTq leads to a cost
savings of around £599.08 per patient. The sensitivity
analysis also confirmed the cost-savings conclusions.
3.2.1 Critique of Economic Evidence
The EAC reviewed the company’s search strategy and the
databases included and concluded that it could be improved
in terms of the date limits (2000–2014) and the search. The
EAC therefore undertook a new search for economic evi-
dence, but they did not find any new evidence on the
technology.
Table 2 continued
Study Patient population and country Intervention and/or
comparator
Study design Main findings
Ye et al.
[44]
Patients with hepatitis B
(n = 204) and healthy
volunteers (n = 60). Only 66
of 204 patients underwent liver
biopsy for comparison with
ARFI
China
VTq, ultrasound-guided
liver biopsy
Prospective diagnostic accuracy,
ARFI measurement with
Siemens Acuson S2000TM
within 3 days of liver biopsy.
No follow-up
Found that ARFI liver stiffness
measurements showed good
correlation with the fibrosis
stage (p = 0.87, p\ 0.001),
and a high diagnostic accuracy
between early/intermediate
and advanced fibrosis stages
(F0–2 vs. F3 = 0.99, F0–2 vs.
F4 = 0.97)
ARFI acoustic radiation force impulse, AUROC area under receiver operating characteristic, BMI body mass index, CI confidence interval, GTP
c-glutamyltranspeptidase, IFN interferon, LB liver biopsy, TE transient elastography, VTq Virtual TouchTM Quantification
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The EAC considered that the model addressed the
decision problem in the scope, but that the structure did not
accurately reflect current clinical pathways for people with
liver fibrosis. Furthermore, it did not include all the rele-
vant costs and outcomes for diagnosing and treating the
condition. No monitoring or treatment costs were included
for people in the F C 2, F3 or F4 fibrosis groups. The EAC
concluded that this was erroneous, as people with less
severe fibrosis may benefit from treatment.
TheEACalso questioned theassumption that people falsely
classifiedasnegative forfibrosiswould not incur any treatment
costs and would re-enter the model as new patients. It was
determined that this was a misleading approach as misdiag-
nosis may incur additional costs (from further diagnostic tests,
inpatient or emergency episodes and treatment). The EAC
considered that a mortality arm would have been useful to
account for the small increased risk associated with LB, but
acknowledged that thiswas likely to have been incorporated in
the chosen tariff cost. The EAC noted that the company used a
cohort approach rather than a per-patient approach as specified
in NICE’s methodology. In order to address these issues, the
EAC revised some of the parameters and re-ran the company’s
model (described further in Sect. 3.2.2).
3.2.2 Additional EAC Economic Evidence
The EAC revised some parameters and re-ran the com-
pany’s model to address the issues mentioned in Sect.
Table 3 Summary of outcome data for meta-analyses
Study Study
population
Comparator to liver
biopsy
Correlation test Liver fibrosis
stage
Sensitivity
(%)
Specificity
(%)
Sporea et al. [34] C VTq Spearman rho = 0.65
(p\ 0.001)
F C 1 69.9 80
F C 2 69.1 79.8
F C 3 74.8 81.5
F4 84.3 76.3
Friedrich-Rust et al.
[32]
B VTq Spearman rho = 0.42
(p\ 0.001)
F C 2 50 90
TE Spearman rho = 0.56
(p\ 0.001)
Not available Not
available
Not
available
Friedrich-Rust et al.
[33]
C VTq Not available Not available Not
available
Not
available
Yamada et al. [39] C VTq Pearson rho = 0.76
(p\ 0.001)
F C 2 92.5 76.2
F C 3 84.6 87.8
Nishikawa et al. [42] C VTq Spearman rho = 0.73
(p\ 0.001)
F C 1 69.1 85.7
F C 2 81.8 87.1
F C 3 88.9 82.5
F4 85.7 86.2
Chen et al. [40] C VTq Spearman rho = 0.70
(p\ 0.001)
F C 2 74.1 87
F C 3 90.2 89.5
F4 88.9 79.8
Rizzo et al. [43] C VTq Not available F C 2 81 70
F C 3 91 86
F4 83 86
TE Not available F C 2 71 71
F C 3 77 85
F4 70 82
Kuroda et al. [41] C VTq Spearman rho = 0.98
(p = 0.002)
Not available Not
available
Not
available
Ye et al. [44] B VTq Spearman rho = 0.87
(p\ 0.001)
Not available Not
available
Not
available
Liu et al. [38] B VTq Spearman rho = 0.85
(p\ 0.001)
F C 2 83.95 83.05
F4 93.1 76.83
TE Spearman rho = 0.81
(p\ 0.001)
F C 2 81.8 71.24
F4 88.1 86.67
TE transient elastography, VTq Virtual TouchTM Quantification
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3.2.1, including treatment and monitoring costs for people
diagnosed with less severe fibrosis (F\ 2), those initially
classed as false negative and a mortality arm. The revised
model was a sequential decision tree incorporating out-
comes for F C 2, F C 3 and F4 fibrosis using VTq, TE
and LB over a 1-year time horizon for adults or children
with chronic hepatitis B or C. Each stage included true
positives, false positives, true negatives and false nega-
tives. Revised prevalence and diagnostic accuracy
parameters for the model were taken mainly from the
EAC’s meta-analyses and applied at each sequential stage
for VTq, TE and LB.
As in the company’s model, LB was treated as the ref-
erence standard with 100 % sensitivity and specificity [9].
The EAC made several assumptions for the model (see
Appendix 4). The unit costs for VTq and TE were esti-
mated using an annuity method and discounted at 3 %, to
give a per-test figure of £15.24 for VTq and £25.90 for TE.
The cost for LB was estimated from NHS reference costs to
be £622 (weighted average of NHS reference codes
GB04D and GB04E) [52]. The costs for antiviral therapy
were taken as £2808 for those at stage F3 and £5680 for
those at stage F4, based on duration of treatment with
peginterferon-alfa and ribavirin [53].
Results from the revised base case are shown in Table 6.
In a scenario where a compatible Siemens ultrasound
machine would need to be purchased along with the VTq
software, using VTq would generate cost savings of £53
per person compared with TE and £434 compared with LB.
If a compatible ultrasound machine was already available,
the cost savings for VTq increased slightly to £57 com-
pared with TE and £438 compared with LB.
The EAC carried out deterministic sensitivity analyses,
varying prevalence rates, sensitivity and specificity for
VTq and TE, distribution of false positives between stages
F2 and F3, unit costs of VTq and TE, usage levels of TE
and antiviral therapy costs. Findings from the sensitivity
analyses showed that VTq remained cost saving across all
scenarios. The key drivers affecting the cost savings per
person were prevalence of liver fibrosis, the distribution of
false positives to other fibrosis stages, the specificity of
VTq and TE for stages F C 2 and F C 3, unit costs of VTq
and TE, and antiviral treatment costs.
Table 4 Pooled estimates with 95 % confidence interval for prevalence, sensitivity and specificity
Study
population
Comparator
to liver biopsy
Liver fibrosis
per stage
No. of
studies
Prevalence
[% (95 % CI)]
Sensitivity
[% (95 % CI)]
Specificity
[% (95 % CI)]
B VTq F C 2 2 43 (6–79) 70 (32–92) 87 (79–92)
F4 1 27 (19–36) 93 (77–99) 77 (66–86)
TE F C 2 1 61 (51–70) 82 (70–90) 71 (55–84)
F4 1 27 (19–36) 88 (73–98) 87 (78–94)
C VTq F C 1 2 91 (83–95) 70 (67–73) 81 (70–88)
F C 2 5 60 (48–71) 78 (70–85) 79 (73–84)
F C 3 5 40 (32–48) 86 (76–92) 84 (81–88)
F4 4 23 (18–29) 85 (80–88) 81 (75–86)
TE F C 2 1 63 (54–71) 71 (61–80) 71 (57–83)
F C 3 1 39 (31–47) 77 (64–80) 85 (75–92)
F4 1 22 (15–29) 70 (51–85) 82 (73–88)
B and C VTq F C 2 7 55 (42–67) 77 (69–84) 81 (76–85)
F4 5 23 (18–29) 85 (81–89) 80 (76–85)
TE F C 2 2 62 (53–70) 76 (64–85) 71 (61–79)
F4 2 23 (14–36) 79 (56–92) 84 (78–88)
Each subgroup is classified as separate study
CI confidence interval, TE transient elastography, VTq Virtual TouchTM Quantification
Table 5 Pooled estimates correlation
Study
population
Comparator to
liver biopsy
Number of
studies
Pooled
correlationa
B VTq 2 0.63
TE 2 0.69
C VTq 4 0.68
TE Not available Not available
B and C VTq 7 0.68 (0.58–0.78)
TE 2 0.69
CI confidence interval, TE transient elastography, VTq Virtual
TouchTM Quantification
a 95 % confidence interval is only provided where the numbers of
studies allow a stable estimate
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3.3 Conclusion of the EAC
The EAC considered that the systematic review provided
by the company was comprehensive and that the inter-
pretation of the evidence was reasonable; however, they
considered that many of the studies included by the
company had overlapping cohorts and should have been
excluded from the review. From the initial 11 studies that
the company included, the EAC agreed with the inclusion
of three studies: two with a population of people with
hepatitis C [33, 34] and one with a population of people
with hepatitis B [32]. Many studies were excluded by the
EAC as the population included was mixed or included
groups not specified in the scope, thus substantially
reducing the available evidence submitted by the
company.
To ensure that all available evidence had been identified,
the EAC repeated the systematic review and performed a
meta-analysis. The EAC’s systematic review identified ten
studies, which included the three identified by the com-
pany, two that had been previously excluded by the com-
pany and five additional studies. The meta-analyses of the
comparators (VTq and TE) to LB filled gaps in the evi-
dence base by providing additional pooled outcome esti-
mates with 95 % CIs.
As expected, prevalence rates generally decreased with
increasing liver fibrosis stage. Overall prevalence for both
VTq and TE (combined study populations) had similar
rates for cirrhosis (F4) (0.23 vs. 0.23) and a lower preva-
lence for significant fibrosis (F C 2) for VTq than for TE
(0.55 vs. 0.62). Pooled estimates (combined study popu-
lations) for correlation were similar for VTq and TE, whilst
the pooled estimates for sensitivity for significant fibrosis
(F C 2) and cirrhosis (F4) were higher for VTq than for TE.
Specificity values for significant fibrosis (F C 2) were
notably higher for VTq than for TE (81 vs. 71 %), but were
closer for cirrhosis (F4) (80 vs. 84 %).
The EAC sequentially remodelled the costs for the
technology and comparators using prevalence, sensitivity,
specificity, test costs and antiviral treatment cost; they
found that the technology (VTq) offers cost savings when
compared to TE and LB. The cost saving against LB was
much larger than when compared to TE. Sensitivity anal-
ysis of the key variables also did not alter the conclusion
that the VTq technology is cost saving. The EAC
acknowledged some limitations of its revised parameters.
Due to the lack of clear data available on prevalence and
diagnostic accuracy at each stage of fibrosis, figures were
extrapolated for the stages in a sequential model rather than
each stage being presented separately. Figures for hepatitis
C at stage F C 3 fibrosis were applied to the whole pop-
ulation because combined data were not available.
4 NICE Guidance
In accordance with NICE’s MTEP process, draft recom-
mendations for the adoption of the VTq device were pro-
duced based on discussion by MTAC, the EAC report and
input from expert advisors. The draft recommendations
were subject to public consultation and MTAC considered
all submitted comments before developing final guidance.
4.1 Preliminary Guidance
In November 2014, MTAC met and reviewed both the
company’s submission and the EAC report, along with
input from expert advisers. Based on this meeting, MTAC
concluded ‘‘that the case for adopting Virtual Touch
Quantification (VTq) software to diagnose and monitor
liver fibrosis is supported by the evidence’’ [2]. MTAC
provisionally recommended the use of VTq in ‘‘adults and
children with chronic hepatitis B or C who need assessment
of liver fibrosis’’.
4.2 Consultation Response
Public comment was invited on the draft recommendations
between 17 December 2014 and 19 January 2015. During
this period, detailed comments (n = 31) were received
from nine consultees: two companies, one EAC (KiTEC),
the Department of Health, two patient organisations, two
Guideline Development Groups and one professional
society [2]. The EAC, in collaboration with the MTEP
team, prepared draft responses to all comments and pre-
sented them to MTAC for consideration in its final guid-
ance meeting. During this meeting the consultation
Table 6 Costs for Virtual TouchTM Quantification and comparators
Expected cost (base case) [£]
Costs for VTq and comparators if ultrasound machine purchased
VTq 1971
TE 2025
LB 2405
VTq cost savings against TE 53
VTq cost savings against LB 434
Costs of VTq and comparators if ultrasound machine not purchased
VTq 1968
TE 2025
LB 2405
VTq cost savings against TE 57
VTq cost savings against LB 438
LB liver biopsy, TE transient elastography, VTq Virtual TouchTM
Quantification
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comments were discussed at length with expert advisers
and EAC representatives.
The detailed consultation comments covered several
areas of concern related to the use of VTq for the assess-
ment of liver fibrosis. Several comments related to the use
of VTq in patients with a high body mass index (BMI). The
EAC responded by clarifying that the currently available
evidence is unclear, with some studies suggesting that BMI
has no interrelation with measurements of VTq or indeed
TE, whilst other studies suggest that it does. Furthermore,
the EAC was unable to adjust for BMI in the meta-analyses
due to the lack of detailed and comparable data.
Disease progression and monitoring was another topic
raised within the consultation process, with the suggestion
that as disease progression for hepatitis B and hepatitis C is
different this may influence the results for VTq. None of
the accepted clinical or economic evidence assessed
monitoring or disease progression. However, Yamada et al.
[39] did investigate the ability of VTq to predict response
to antiviral therapy based on hepatitis genotype. They
found that VTq could not predict response with genotype 2
hepatitis C but could with genotype 1 hepatitis C.
The potential use of VTq in paediatric patient popula-
tions attracted comment. It was suggested that there were
likely benefits of VTq for children since more invasive
techniques such as LB could be avoided. The EAC iden-
tified two published studies that included a paediatric
population, but these were subsequently excluded due to
mixed patient cohorts. Both were pilot studies and con-
cluded that VTq showed promise in non-invasive staging of
liver fibrosis in children [54, 55]. As described in Sect. 3.1,
the EAC also identified an ongoing clinical trial with a
paediatric population in Canada [37]. Although the results
of the trial are not yet available, the study consists of
children with hepatitis B, hepatitis C or non-alcoholic fatty
liver disease, and it is evaluating the safety/efficacy of TE,
VTq and magnetic resonance imaging.
Concern was raised regarding the impact of hepatic
inflammation on liver elasticity and associated VTq read-
ings. Of the evidence included by the EAC, only two
papers assessed inflammation (note that inflammation was
outside the NICE scope for VTq). Nishikawa et al. [42]
compared VTq and LB in diagnosed chronic hepatitis C
patients in Japan, and concluded that there was no corre-
lation between ARFI and inflammation when patients with
different fibrosis stages were analysed separately using
multivariate regression analysis. In contrast, in their study
of hepatitis C patients in Taiwan, Chen et al. [40] found
evidence that inflammation significantly affects the mea-
surement of liver fibrosis using VTq. New evidence pro-
vided to the EAC assessed ARFI/VTq/histological variance
amongst patients referred for a LB [56]. The unadjusted
univariate analysis found no significant difference in ARFI/
histological variance between non-viral and viral patients;
however, the EAC notes that interpretation of this abstract
is limited given the lack of subgroup analysis and detailed
study information. MTAC considered this additional evi-
dence in determining its final guidance.
The issues of inter-operator and intra-observer variability
were raised throughout the consultation process. Although
this was outside the NICE scope for VTq, the EAC
reviewed the available evidence. Rizzo et al. [43] per-
formed a range of analyses which included inter-observer
agreement. The Bland-Altman method was used to assess
agreement of ARFI performed by two different sonogra-
phers for 21 patients. There was no significant difference
between VTq values, indicating good agreement. Chen
et al. [40] assessed intra-observer correlations of ARFI liver
stiffness measurements (LSM) using an intra-class corre-
lation coefficient (ICC). Independent LSMs were performed
on two separate occasions in 20 patients. The same hepa-
tologist was involved on both occasions, and the study
found statistically significant agreement/consensus. The
EAC concluded that these two studies provide reasonable
evidence for acceptable agreement/consensus between the
observers when assessing VTq/ARFI measurements.
Expert advisers were approached for an opinion on the
generalisability of the research, conducted in other Euro-
pean and Asian countries, to the UK population, and
regarding whether there were likely to be differences in the
overall VTq measurements between ethnic groups. Three
experts responded: the first expert adviser commented that
obesity, which may be less prevalent in some Asian
countries, can cause the VTq technique to fail more often
and may cause the results to be more variable. Another
expert adviser remarked that the German and Romanian
studies may not be applicable to a UK population as the
UK population with hepatitis B and hepatitis C is a
worldwide, rather than a European, population. The final
expert advisor commented that they consider that the study
populations would be applicable to the UK as long as they
are corrected for age, BMI and other factors. These factors,
which would be applicable to TE as well as VTq, could not
be accounted for in the EAC’s meta-analysis using the
current available clinical evidence. In light of this, the EAC
considers that a study using a UK population to compare
VTq, TE and LB would be beneficial, and should appro-
priately allow for such confounding factors, potentially
through suitable subgroup analysis.
4.3 Final Guidance
An MTAC meeting was held on 19 February 2015 to
produce the final medical technology guidance for the use
of VTq to diagnose and monitor liver fibrosis in chronic
hepatitis B and C (MTG27), which was published by NICE
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in September 2015 [2], and included the following
recommendations.
1. The case for adopting VTq software to diagnose and
monitor liver fibrosis is supported by the evidence. VTq
is as accurate as TE in diagnosing and staging liver
fibrosis, and may offer other benefits in terms of imaging
the liver and sampling selected areas to assess fibrosis
and identify associated pathologies. By avoiding liver
biopsies, it may also benefit people whose liver fibrosis
needs monitoring. Cost savings through adopting VTq
will be greater in hospitals in which LB is the primary
method for diagnosing and monitoring liver fibrosis.
2. VTq should be considered as an option for people with
chronic hepatitis B or C who need assessment of liver
fibrosis.
3. Cost modelling suggests that using VTq is cost saving
compared with TE and LB, whether or not a compat-
ible Siemens ultrasound machine needs to be pur-
chased. Compared with TE, the estimated overall cost
saving for VTq is around £53 per person. This saving
assumes that 10 % of the ultrasound machine capacity
would be used for VTq measurements, leaving 90 % to
be applied to other uses. Compared with LB, the
corresponding saving is around £434 per person.
5 Challenges
During the course of reviewing the clinical evidence for
VTq, the EAC encountered several challenges. The limited
availability of clinical evidence for the use of VTq in hep-
atitis B and C patients was one of the main challenges. Many
of the studies identified had overlapping patient populations,
which is why the EAC subsequently rejected many of the
studies included by the company. The company’s systematic
review did not adequately reflect the scope specified by
NICE; therefore, the EAC repeated this step. The EAC’s
systematic review identified ten studies, which included the
three identified by the company, two that had been previ-
ously excluded by the company and five additional studies.
Meta-analyses of the comparators (VTq and TE) for LB
was carried out by the EAC to fill the gaps in the evidence
base by providing additional pooled outcome estimates
with 95 % CIs. The pooled estimates of prevalence, sen-
sitivity and specificity were the parameters required for the
economic modelling and pooled estimates for correlation
were also provided. The meta-analysis provided pooled
estimates for the various study populations (hepatitis B,
hepatitis C and combined study populations) and for liver
fibrosis stage. Not all liver fibrosis stages could be included
in the meta-analyses; however, pooled estimates were
available for all F C 2 and F4 subgroups.
Since no economic evidence was available for the VTq
technology, the company submitted a de novo cost model.
The EAC considered that the proposed model generally
addressed the scope issued by NICE, but nonetheless had
important issues that needed to be considered. In particular,
the model structure proposed by the company neither
reflected the clinical pathway for patients with fibrosis
(both the current pathways with TE and LB and the pro-
posed pathway with VTq) nor took into account all relevant
costs and outcomes for diagnosing and treating liver
fibrosis. On this basis, the EAC considered it necessary to
revise the company’s model, which resulted in a cost
saving of £53 (against TE) and £434 (against LB).
In summary, there are several challenges in assessing
medical technology arising from limitations in the avail-
able evidence. Specifically, for VTq, it was fortunate that
sufficient evidence was available during the MTAC process
to enable meta-analysis and more precise economic mod-
elling. This evaluation has added to the evidence for the
use of VTq in the assessment and monitoring of liver
fibrosis in hepatitis B and hepatitis C patients in the UK.
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Appendix 1: Selection criteria used to identify
relevant published studies
Appendix 2: Clinical evidence search strategy
Ovid MEDLINE in-process and other non-indexed cita-
tions and Ovid MEDLINE 1946 to present, and
EMBASE 1980 to 10 July 2014; searched on 10 July 2014
The Cochrane Library, to present; searched on 11 July
2014.
Database of Abstracts of reviews of Effects (DARE), to
present; searched on 11 July 2014.
Inclusion criteria
Population Adults or children with chronic hepatitis B or C in
whom assessment of liver fibrosis is indicated
Intervention The Virtual TouchTM Quantification (VTq)
software application used with the Siemens
Virtual TouchTM Tissue Imaging systems (the
Acuson S2000TM or S3000TM ultrasound
platforms)
Outcomes Correlation in assessment of stage of liver disease
Sensitivity and specificity (using AUROC) in
assessment of liver fibrosis
Correlation in assessment of stage of fibrosis using
Metavir score
Use of antiviral drugs
Quality-of-life measures
Hospital bed usage and length of stay
Requirement for liver biopsy
Device-related adverse events
Study design Diagnostic accuracy studies
Language
restrictions
English language only
Foreign language papers with English abstracts
could be included
Search dates 2009–current
Exclusion criteria
Population Mixed patient cohort, use of a fibrosis score other
than Metavir, overlapping cohorts with other
identified populations
Study design Case studies, editorials, letters, reviews
Interventions No restriction
AUROC area under receiver operating characteristic
1 virtual touch tissue quantification.mp.
2 acoustic radiation force impulse.mp.
3 acoustic radiation force impulse imaging.mp.
4 acoustic radiation force impulse elastography.mp.
5 ARFI elastography.mp.
6 elasticity imaging techniques.mp. or Elasticity Imaging
Techniques/
7 liver diseases.mp. or Liver Diseases/
8 liver fibrosis.mp. or Liver Cirrhosis/
9 Hepatitis/ or Hepatitis B, Chronic/ or Hepatitis, Viral, Human/ or
Hepatitis B/ or Hepatitis C/ or Hepatitis C, Chronic/ or
hepatitis.mp.
10 prognosis.mp. or Prognosis/
11 predictive.mp. or ‘‘Predictive Value of Tests’’/
12 receiver operating characteristic.mp. or ROC Curve/
13 adverse event.mp.
14 ‘‘Sensitivity and Specificity’’/ or diagnostic accuracy.mp.
15 antiviral.mp. or Antiviral Agents/
16 quality of life.mp. or ‘‘Quality of Life’’/
17 1 or 2 or 3 or 4 or 5 or 6
18 7 or 8 or 9
19 10 or 11 or 12 or 13 or 14 or 15 or 16
20 17 and 18 and 19
21 Limit 20 to English language
22 Limit 21 to yr = ‘‘2009–current’’
23 Limit 22 to humans
24 Remove duplicates from 23
Search all text Acoustic radiation force impulse
OR Search all text ARFI elastography
OR Search all text ARFI
OR Search all text Virtual touch tissue quantification
OR Search all text Elasticity imaging
Any field Acoustic radiation force impulse OR
Any field Virtual touch tissue quantification OR
Any field Elasticity imaging
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Appendix 3: PRISMA flow diagram showing the company’s search (dotted box) and the External
Assessment Centre (EAC) search results
Appendix 4: Model assumptions for clinical
parameters
References
1. National Institute for Health and Care Excellence. NICE medical
technologies evaluationprogramme.2015. https://www.nice.org.uk/
about/what-we-do/our-programmes/nice-guidance/nice-medical-
technologies-evaluation-programme. Accessed 1 Jun 2016.
2. National Institute for Health and Care Excellence. Virutal Touch
Quantification to diagnose and monitor liver fibrosis in chronic
hepatitis B and C: Medical Technology Guidance (MTG27).
2015. https://www.nice.org.uk/guidance/mtg27/. Accessed 1 Jun
2016.
18 of 23
External Assessment Centre report: Virtual Touch Quanﬁcaon to diagnose and monitor liver ﬁbrosis.
Date: August 2014
Titles and abstracts 
identified from bibliographic 
databases and screened for 
potential relevance = 70
Siemens Clinical Abstracts 
02/2013  = 88 
Excluded at title and 
abstract screening = 47
Potentially relevant 
publications = 23
Could not be obtained = 0
Potentially relevant 
publications obtained as full 
text = 23
Authors contacted for 
further information = 0
Conference abstracts 
included after screening = 0  
Total number of studies 
included in the review  = 11
Included by EAC 
aer exclusion 
by company
n=2
Company
EAC
Excluded by EAC due to 
overlapping cohorts
Included by EAC in 
their review
Titles and abstracts idenﬁed 
from databases and screened for 
relevance 
Potenally relevant publicaons 
obtained as full text
Total number of studies 
included in the review
Total number of 
studies not previously 
idenﬁed by company
Assumption and justification
People categorised as false negative for fibrosis would return and
be re-diagnosed as true positive within 1 year
Prevalence rates for stages of fibrosis were different for VTq and
TE based on the EAC’s meta-analyses. The combined hepatitis
B and C prevalence rates for VTq were used for TE and liver
biopsy in the model to ensure compatibility
Combined hepatitis B and C prevalence and diagnostic accuracy
figures for F C 3 fibrosis were not available from the meta-
analysis. The EAC therefore used figures for hepatitis C across
the model for this stage
Treatment delay resulting from misdiagnosis was unlikely to have
a clinical impact and so long-term modelling of disease
progression was not needed. According to published clinical
evidence and expert advice gathered by the EAC, progression in
both hepatitis B and C is relatively slow
People diagnosed as being at stage F C 2 had fibrosis and those at
stage F B 1 did not
The majority of misclassified (false positive) cases for VTq and
TE would be diagnosed as having F2 fibrosis. A proportion of
those with F2 fibrosis would be misclassified as having F3 or F4
fibrosis. These proportions were chosen arbitrarily and subjected
to sensitivity analyses
People diagnosed with F3 or F4 fibrosis would have antiviral
therapy
A mortality risk of 0.003 would apply to liver biopsy
EAC External Assessment Centre, TE transient elastography, VTq
Virtual TouchTM Quantification
J. A. Summers et al.
3. Dhillon R, Parakevopoulu M. Hepatitis B and C. J Intensive Care
Soc. 2014;15(2):135–41.
4. Foster G, Campbell L. Hepatitis B. 2012. http://www.britishliver
trust.org.uk/liver-information/liver-conditions/hepatitis-b/. Acces-
sed 1 Jun 2016.
5. World Health Organization. Hepatitis C. Fact sheet. 2015. http://
www.who.int/mediacentre/factsheets/fs164/en/. Accessed 1 Jun
2016.
6. NHS Choices. Hepatitis C. 2015. http://www.nhs.uk/conditions/
Hepatitis-C/Pages/Introduction.aspx. Accessed 1 Jun 2016.
7. National Institute for Health and Care Excellence. NICE rec-
ommends three new treatment options for hepatitis C in draft
guidance. 2015. https://www.nice.org.uk/news/press-and-media/
nice-recommends-new-treatment-options-for-hepatitis-c. Acces-
sed 1 Jun 2016.
8. National Institute for Health and Care Excellence. Hepatits B
(chronic): diagnosis and management: NICE Guidelines [CG165].
2013. https://www.nice.org.uk/guidance/cg165.Accessed 1 Jun 2016.
9. Siemens. Virtual Touch Quantification to diagnose and monitor
liver fibrosis: Company submission of evidence for NICE Med-
ical Technologies Evaluation Programme. 2014.
10. National Institute for Health and Care Excellence. Medical
technology guidance SCOPE Virtual Touch Quantification to
diagnose and monitor liver fibrosis. 2014. Available at:https://
www.nice.org.uk/guidance/gid-mt210/documents/virtual-touch-
quantification-to-diagnose-and-monitor-liver-fibrosis-final-
scope2. Accessed Aug 2016.
11. Calvaruso V, et al. Acoustic radiation force impulse is better than
transient elasography in assessing liver fibrosis in chronic hep-
atitis C using collagen proportionate area as reference. Hepatol-
ogy. 2013;58(Suppl. 1):919A.
12. Aoki T, et al. Analysis of risk factors for aiming at early detection
of hepatocellular carcinoma. Hepatology. 2013;58(Suppl. 1):958A.
13. Atzori S, et al. Non-invasive assessment of liver fibrosis: acoustic
radiation force impulse of the left lobe correlates best with Ishak
histology score. Hepatology. 2013;58(Suppl. 1):964A.
14. Sporea I, et al. The feasibility of shear-wave elastographic
methods for non-invasive assessment of liver fibrosis in chronic
viral hepatitis patients. Ultraschall Med. 2013;34.
15. Schneider MD, et al. Non-invasive assessment of liver fibrosis
with acoustic radiation force imaging and transient elastography
in chronic viral hepatitis. Ultraschall Med. 2013;34.
16. Cassinotto C, et al. Assessment of liver fibrosis with ARFI: com-
parisonwithMandXLprobles ofFibroscan andFibroTest in chronic
liver diseases [abstract]. Hepatol Int. 2013;7(Suppl. 1):S487.
17. Badea R, et al. ARFI performance in the noninvasive assessment
of HCV cirrhosis, compared to transient elastography and FIB
score [abstract]. Hepatol Int. 2013;7(Suppl. 1):S680.
18. Bota S, et al. ARFI elastography vs. transient elastography: which
one is more influenced by high aminotransferases values. Hepa-
tology. 2012;56(Suppl. 1):839A.
19. Le LT, et al. Comparison of liver stiffness values by virtual touch
ARFI and fibroscan TE in large sample study of 554 cases. J Med
Imaging Radiat Oncol. 2012;56(Suppl. 1):120.
20. Sporea I, Sirli R, Bota S, et al. Comparative study concerning the
value of acoustic radiation force impulse elastography (ARFI) in
comparison with transient elastography (TE) for the assessment
of liver fibrosis in patients with chronic hepatitis B and C.
Ultrasound Med Biol. 2012;38(8):1310–6.
21. Sporea I, et al. Which elastographic method (transient elastog-
raphy or ARFI) is more useful for liver fibrosis evaluation in
patients with chronic hepatitis C? An international multicenter
study. Gastroenterology. 2012;142(Suppl. 1):S1013.
22. Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of
Acoustic Radiation Force Impulse imaging for the staging of liver
fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19(2):e212–9.
23. Karlas T, Pfrepper C, Wiegand J, et al. Acoustic radiation force
impulse imaging (ARFI) for non-invasive detection of liver
fibrosis: examination standards and evaluation of interlobe dif-
ferences in healthy subjects and chronic liver disease. Scand J
Gastroenterol. 2011;46(12):1458–67.
24. Sporea I, S¸irli R, Popescu A, et al. Is it better to use two elas-
tographic methods for liver fibrosis assessment? World J Gas-
troenterol. 2011;17(33):3824–9.
25. Calvaruso V, et al. Comparison of transient elastography (TE)
and acoustic radiation force impulse (ARFI) for noninvasive
staging of liver fibrosis in patients with chronic hepatitis C.
Hepatology. 2010;52(Suppl. 1):1237A.
26. Sporea I, et al. Which is the best noninvasive ultrasound method
for the evaluation of liver fibrosis? Gastroenterology.
2010;138(Suppl. 1):S511.
27. Lupsor M, Badea R, Stefanescu H, et al. Performance of a new
elastography method (ARFI technology) compared to unidi-
mensional transient elastography in the noninvasive assessment
of chronic hepatitis C. Preliminary results. J Gastrointestin Liver
Dis. 2009;18(3):303–10.
28. Lupsor M, et al. Performance of acoustic radiation force impulse
imaging in the noninvasive assessment of liver firbosis in com-
parison to unidimensional transient elastography. J Hepatol.
2010;52(Suppl. 1):S165–6.
29. Sporea I, Badea R, Sirli R, et al. How efficient is acoustic radi-
ation force impulse elastography for the evaluation of liver
stiffness? Hepat Mon. 2011;11(7):532–8.
30. Bota S, Herkner H, Sporea I, et al. Meta-analysis: ARFI elas-
tography versus transient elastography for the evaluation of liver
fibrosis. Liver Int. 2013;33(8):1138–47.
31. Nierhoff J, Cha´vez Ortiz AA, Herrmann E, et al. The efficiency
of acoustic radiation force impulse imaging for the staging of
liver fibrosis: a meta-analysis. Eur Radiol. 2013;23(11):3040–53.
32. Friedrich-Rust M, Buggisch P, de Knegt RJ, et al. Acoustic
radiation force impulse imaging for non-invasive assessment of
liver fibrosis in chronic hepatitis B. J Viral Hepat.
2013;20(4):240–7.
33. Friedrich-Rust M, Lupsor-Platon M, de Knegt R, et al. Acoustic
radiation force impulse-imaging in comparison to transient elas-
tography for non-invasive assessment of liver fibrosis in chronic
hepatitis C: a prospective international multicenter study [abstract
no. P1011]. J Hepatol. 2014;60(Suppl. 1):S411–2.
34. Sporea I, Bota S, Peck-Radosavljevic M, et al. Acoustic radiation
force impulse elastography for fibrosis evaluation in patients with
chronic hepatitis C: an international multicenter study. Eur J
Radiol. 2012;81(12):4112–8.
35. Centre Hospitalier de l’Universite´ de Montre´al and Canadian
Institutes of Health Research Montreal Canada. Nonivasive
staging of liver fibrosis: MR vs ultrasound (ELF) [ClinicalTri-
als.gov identifier NCT02044523]. 2015. US National Institutes of
Health, ClinicalTrials.gov. http://clinicaltrials.gov. Accessed 30
Aug 2016.
36. Severance Hospital and Yonsei University Seoul Republic of
Korea. Evaluation of liver fibrosis staging with acoustic radiation
force impulse elastography [ClinicalTrials.gov identifier
NCT01283230]. 2015. US National Institutes of Health, Clini-
calTrials.gov. http://clinicaltrials.gov. Accessed 30 Aug 2016.
37. University of Michigan Michigan United States. Ultrasound
based acoustic radiation force impulse, shear wave velocity
imaging in pediatric patients undergoing liver biopsy [Clini-
calTrials.gov identifier NCT01781208]. 2015. US National
Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov.
Accessed 30 Aug 2016.
38. Liu Y, Dong CF, Yang G, et al. Optimal linear combination of
ARFI, transient elastography and APRI for the assessment of
fibrosis in chronic hepatitis B. Liver Int. 2015;35(3):816–25.
Virtual VTq for the Diagnosis and Monitoring of Liver Fibrosis in Hepatitis B and C
39. Yamada R, Hiramatsu N, Oze T, et al. Significance of liver
stiffness measurement by acoustic radiation force impulse (ARFI)
among hepatitis C patients. J Med Virol. 2014;86(2):241–7.
40. Chen SH, Li YF, Lai HC, et al. Effects of patient factors on
noninvasive liver stiffness measurement using acoustic radiation
force impulse elastography in patients with chronic hepatitis C.
BMC Gastroenterol. 2012;12:105.
41. Kuroda H, Kakisaka K, Tatemichi Y, et al. Non-invasive evalu-
ation of liver fibrosis using acoustic radiation force impulse
imaging in chronic hepatitis patients with hepatitis C virus
infection. Hepatogastroenterology. 2010;57(102–103):1203–7.
42. Nishikawa T, Hashimoto S, Kawabe N, et al. Factors correlating
with acoustic radiation force impulse elastography in chronic
hepatitis C. World J Gastroenterol. 2014;20(5):1289–97.
43. Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of tran-
sient elastography and acoustic radiation force impulse for non-
invasive staging of liver fibrosis in patients with chronic hepatitis
C. Am J Gastroenterol. 2011;106(12):2112–20.
44. Ye XP, Ran HT, Cheng J, et al. Liver and spleen stiffness mea-
sured by acoustic radiation force impulse elastography for non-
invasive assessment of liver fibrosis and esophageal varices in
patients with chronic hepatitis B. J Ultrasound Med. 2012;31(8):
1245–53.
45. Stamuli E, Kruger J, Hutton J. Cost-effectiveness of ultrasound
elastography in the assessment of liver fibrosis: economic report
CEP08053. 2009. http://nhscep.useconnect.co.uk/CEPProducts/
Catalogue.aspx. Accessed 1 Jun 2016.
46. Steadman R, Myers RP, Leggett L, et al. A health technology
assessment of transient elastography in adult liver disease. Can J
Gastroenterol. 2013;27(3):149–58.
47. Shah A, et al. Acoustic Radiation Force Imaging (ARFI) is able
to identify early fibrosis in chronic liver disease results in 169
patients. United Kingdom Radiological Congress; 10–12 Jun
2013; Liverpool.
48. Crespo G, Ferna´ndez-Varo G, Marin˜o Z, et al. ARFI, FibroScan,
ELF, and their combinations in the assessment of liver fibrosis: a
prospective study. J Hepatol. 2012;57(2):281–7.
49. Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic
radiation force impulse elastography for fibrosis staging of
chronic liver disease: a pilot study. Liver Int. 2010;30(4):538–45.
50. Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in
viral hepatitis: noninvasive assessment with acoustic radiation
force impulse imaging versus transient elastography. Radiology.
2009;252(2):595–604.
51. Toshima T, Shirabe K, Takeishi K, et al. New method for
assessing liver fibrosis based on acoustic radiation force impulse:
a special reference to the difference between right and left liver.
Gastroenterology. 2011;46(5):705–11.
52. Department of Health. NHS reference costs 2012 to 2013. 2013.
https://www.gov.uk/government/publications/nhs-reference-costs-
2012-to-2013. Accessed 1 Jun 2016.
53. National Institute for Health and Care Excellence. Peginterferon
alfa and ribavirin for the treatment of chronic hepatitis C NICE
technology appraisal [TA200]. London: NICE; 2010.
54. Noruegas M, Matos H, Gonc¸alves I, et al. Acoustic radiation
force impulse-imaging in the assessment of liver fibrosis in
children. Pediatr Radiol. 2012;42(2):201–4.
55. Hanquinet S, Rougemont AL, Courvoisier D, et al. Acoustic
radiation force impulse (ARFI) elastography for the noninvasive
diagnosis of liver fibrosis in children. Pediatr Radiol. 2013;43(5):
545–51.
56. Sherman D, et al. Factors contributing to variance between ARFI
elastography and liver histology: results of a large unselected
consecutive series with simultaneous biopsy of ARFI measure-
ment site [abstract]. European Association for the Study of Liver
Disease meeting, British Society of Gastroenterology meeting
and Radiological Society of North America meeting, 2014,
London, Manchester and Chicago.
J. A. Summers et al.
